Literature DB >> 20847048

Stable alpha-synuclein oligomers strongly inhibit chaperone activity of the Hsp70 system by weak interactions with J-domain co-chaperones.

Marie-Pierre Hinault1, America Farina Henriquez Cuendet, Rayees U H Mattoo, Mounir Mensi, Giovanni Dietler, Hilal A Lashuel, Pierre Goloubinoff.   

Abstract

α-Synuclein aggregation and accumulation in Lewy bodies are implicated in progressive loss of dopaminergic neurons in Parkinson disease and related disorders. In neurons, the Hsp70s and their Hsp40-like J-domain co-chaperones are the only known components of chaperone network that can use ATP to convert cytotoxic protein aggregates into harmless natively refolded polypeptides. Here we developed a protocol for preparing a homogeneous population of highly stable β-sheet enriched toroid-shaped α-Syn oligomers with a diameter typical of toxic pore-forming oligomers. These oligomers were partially resistant to in vitro unfolding by the bacterial Hsp70 chaperone system (DnaK, DnaJ, GrpE). Moreover, both bacterial and human Hsp70/Hsp40 unfolding/refolding activities of model chaperone substrates were strongly inhibited by the oligomers but, remarkably, not by unstructured α-Syn monomers even in large excess. The oligomers acted as a specific competitive inhibitor of the J-domain co-chaperones, indicating that J-domain co-chaperones may preferably bind to exposed bulky misfolded structures in misfolded proteins and, thus, complement Hsp70s that bind to extended segments. Together, our findings suggest that inhibition of the Hsp70/Hsp40 chaperone system by α-Syn oligomers may contribute to the disruption of protein homeostasis in dopaminergic neurons, leading to apoptosis and tissue loss in Parkinson disease and related neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20847048      PMCID: PMC2992251          DOI: 10.1074/jbc.M110.127753

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  59 in total

1.  Sequential mechanism of solubilization and refolding of stable protein aggregates by a bichaperone network.

Authors:  P Goloubinoff; A Mogk; A P Zvi; T Tomoyasu; B Bukau
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

2.  Size-dependent disaggregation of stable protein aggregates by the DnaK chaperone machinery.

Authors:  S Diamant; A P Ben-Zvi; B Bukau; P Goloubinoff
Journal:  J Biol Chem       Date:  2000-07-14       Impact factor: 5.157

Review 3.  The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.

Authors:  M G Spillantini; M Goedert
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

4.  Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease?

Authors:  M S Goldberg; P T Lansbury
Journal:  Nat Cell Biol       Date:  2000-07       Impact factor: 28.824

5.  Mechanism of regulation of hsp70 chaperones by DnaJ cochaperones.

Authors:  T Laufen; M P Mayer; C Beisel; D Klostermeier; A Mogk; J Reinstein; B Bukau
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

6.  Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.

Authors:  K A Conway; J D Harper; P T Lansbury
Journal:  Biochemistry       Date:  2000-03-14       Impact factor: 3.162

7.  Its substrate specificity characterizes the DnaJ co-chaperone as a scanning factor for the DnaK chaperone.

Authors:  S Rüdiger; J Schneider-Mergener; B Bukau
Journal:  EMBO J       Date:  2001-03-01       Impact factor: 11.598

8.  Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons.

Authors:  D D Murphy; S M Rueter; J Q Trojanowski; V M Lee
Journal:  J Neurosci       Date:  2000-05-01       Impact factor: 6.167

9.  The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease.

Authors:  B C Campbell; C A McLean; J G Culvenor; W P Gai; P C Blumbergs; P Jäkälä; K Beyreuther; C L Masters; Q X Li
Journal:  J Neurochem       Date:  2001-01       Impact factor: 5.372

10.  Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease.

Authors:  M J Volles; S J Lee; J C Rochet; M D Shtilerman; T T Ding; J C Kessler; P T Lansbury
Journal:  Biochemistry       Date:  2001-07-03       Impact factor: 3.162

View more
  37 in total

Review 1.  Drug targets from genetics: α-synuclein.

Authors:  Karin M Danzer; Pamela J McLean
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

Review 2.  Molecular chaperones in Parkinson's disease--present and future.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

3.  Reactivation of protein aggregates by mortalin and Tid1--the human mitochondrial Hsp70 chaperone system.

Authors:  Ohad Iosefson; Shelly Sharon; Pierre Goloubinoff; Abdussalam Azem
Journal:  Cell Stress Chaperones       Date:  2011-08-03       Impact factor: 3.667

Review 4.  Molecular chaperones and co-chaperones in Parkinson disease.

Authors:  Hemi Dimant; Darius Ebrahimi-Fakhari; Pamela J McLean
Journal:  Neuroscientist       Date:  2012-07-24       Impact factor: 7.519

5.  GroEL and CCT are catalytic unfoldases mediating out-of-cage polypeptide refolding without ATP.

Authors:  Smriti Priya; Sandeep Kumar Sharma; Vishal Sood; Rayees U H Mattoo; Andrija Finka; Abdussalam Azem; Paolo De Los Rios; Pierre Goloubinoff
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-12       Impact factor: 11.205

6.  Purification of hsp104, a protein disaggregase.

Authors:  Elizabeth A Sweeny; Morgan E DeSantis; James Shorter
Journal:  J Vis Exp       Date:  2011-09-30       Impact factor: 1.355

Review 7.  Targeting heat shock proteins to modulate α-synuclein toxicity.

Authors:  Daryl Rhys Jones; Simon Moussaud; Pamela McLean
Journal:  Ther Adv Neurol Disord       Date:  2014-01       Impact factor: 6.570

8.  Physical interaction between bacterial heat shock protein (Hsp) 90 and Hsp70 chaperones mediates their cooperative action to refold denatured proteins.

Authors:  Hitoshi Nakamoto; Kensaku Fujita; Aguru Ohtaki; Satoru Watanabe; Shoichi Narumi; Takahiro Maruyama; Emi Suenaga; Tomoko S Misono; Penmetcha K R Kumar; Pierre Goloubinoff; Hirofumi Yoshikawa
Journal:  J Biol Chem       Date:  2014-01-12       Impact factor: 5.157

Review 9.  Expanding role of molecular chaperones in regulating α-synuclein misfolding; implications in Parkinson's disease.

Authors:  Sandeep K Sharma; Smriti Priya
Journal:  Cell Mol Life Sci       Date:  2016-08-13       Impact factor: 9.261

Review 10.  α-Synuclein oligomers and clinical implications for Parkinson disease.

Authors:  Lorraine V Kalia; Suneil K Kalia; Pamela J McLean; Andres M Lozano; Anthony E Lang
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.